{
    "pmcid": "10170451",
    "qa_pairs": {
        "What is a significant challenge in developing S2-based vaccines for SARS-CoV-2?": [
            "Low immunogenicity of S2-based antigens",
            "High variability of the S2 subunit",
            "Lack of conserved regions in the S2 subunit",
            "Inability to induce neutralizing antibodies"
        ],
        "What is the primary role of the S2 subunit in the SARS-CoV-2 spike protein?": [
            "Facilitating membrane fusion",
            "Binding to the ACE2 receptor",
            "Evading neutralizing antibodies",
            "Initiating viral replication"
        ],
        "What strategy is suggested to enhance the therapeutic efficacy of S2-targeted therapies?": [
            "Combining them with RBD-specific antibodies or ACE2 mimics",
            "Increasing the dosage of S2-targeted therapies",
            "Using only S2-targeted therapies without other interventions",
            "Focusing solely on the S1 subunit for therapeutic development"
        ],
        "Which element in the S2 subunit is crucial for membrane fusion and can be targeted by antibodies for broad coronavirus neutralization?": [
            "Fusion Peptide (FP)",
            "Receptor-Binding Domain (RBD)",
            "N-terminal Domain (NTD)",
            "Transmembrane Domain (TM)"
        ],
        "Why are nanobodies considered promising candidates for targeting the S2 subunit of SARS-CoV-2?": [
            "They can access cryptic epitopes within the S2 subunit",
            "They have a higher binding affinity than conventional antibodies",
            "They are less likely to induce immune evasion",
            "They are more stable than conventional antibodies"
        ]
    }
}